NO128024B - - Google Patents
Download PDFInfo
- Publication number
- NO128024B NO128024B NO691122A NO112269A NO128024B NO 128024 B NO128024 B NO 128024B NO 691122 A NO691122 A NO 691122A NO 112269 A NO112269 A NO 112269A NO 128024 B NO128024 B NO 128024B
- Authority
- NO
- Norway
- Prior art keywords
- compound
- compounds
- animals
- temperature
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 8
- -1 peroxy compound Chemical class 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 14
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000001968 nicotinic acid Nutrition 0.000 description 5
- 239000011664 nicotinic acid Substances 0.000 description 5
- 229960003512 nicotinic acid Drugs 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000055 hyoplipidemic effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 241000700198 Cavia Species 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229940125890 compound Ia Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- GLVYLTSKTCWWJR-UHFFFAOYSA-N 2-carbonoperoxoylbenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1C(O)=O GLVYLTSKTCWWJR-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XHUXLSXLIAXUHB-UHFFFAOYSA-N CC(C)(CC([N+]([O-])=CC=C1)=C1C(O)=O)OC(C=C1)=CC=C1Cl Chemical compound CC(C)(CC([N+]([O-])=CC=C1)=C1C(O)=O)OC(C=C1)=CC=C1Cl XHUXLSXLIAXUHB-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229910001006 Constantan Inorganic materials 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- OVXWQHGCVNBEEC-UHFFFAOYSA-N [2-(4-chlorophenoxy)-2-methylpropyl] pyridine-3-carboxylate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)COC(=O)C1=CC=CN=C1 OVXWQHGCVNBEEC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 150000004966 inorganic peroxy acids Chemical class 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB03687/67A GB1213162A (en) | 1966-11-16 | 1967-03-23 | Serum lipid lowering pyridine derivatives and their preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO128024B true NO128024B (cg-RX-API-DMAC10.html) | 1973-09-17 |
Family
ID=39719165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO691122A NO128024B (cg-RX-API-DMAC10.html) | 1967-03-23 | 1969-03-18 |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS5039667B1 (cg-RX-API-DMAC10.html) |
| DK (1) | DK126651B (cg-RX-API-DMAC10.html) |
| FI (1) | FI49406C (cg-RX-API-DMAC10.html) |
| NO (1) | NO128024B (cg-RX-API-DMAC10.html) |
| SE (1) | SE347262B (cg-RX-API-DMAC10.html) |
-
1969
- 1969-03-13 FI FI690744A patent/FI49406C/fi active
- 1969-03-18 NO NO691122A patent/NO128024B/no unknown
- 1969-03-20 DK DK151969AA patent/DK126651B/da unknown
- 1969-03-24 JP JP6921746A patent/JPS5039667B1/ja active Pending
- 1969-03-25 SE SE04195/69A patent/SE347262B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE347262B (cg-RX-API-DMAC10.html) | 1972-07-31 |
| FI49406B (cg-RX-API-DMAC10.html) | 1975-02-28 |
| FI49406C (fi) | 1975-06-10 |
| JPS5039667B1 (cg-RX-API-DMAC10.html) | 1975-12-18 |
| DK126651B (da) | 1973-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7550457B2 (en) | Pharmaceutically effective compounds | |
| EP4592285A1 (en) | Fused ring compound having glp-1 receptor agonist effect | |
| EP4114408A1 (fr) | Dérivés de nicotinamide mononucléotide et de bis-nicotinamide dinucléotide pour le traitement de l'arythmie | |
| US20220241247A1 (en) | Pharmacological agents for treating protein aggregation diseases of the eye | |
| GB2184653A (en) | Dementia improving and therapeutic agents | |
| EP0087378B1 (fr) | Ethers-oximes d'alcoylaminoalcools comme médicaments, produits nouveaux et procédés pour leur préparation | |
| JP7730336B2 (ja) | 同位体標識トラピジル誘導体 | |
| JPS61183222A (ja) | ピロール‐３‐カルボキシレート強心剤 | |
| US3002978A (en) | Glyceryl pyrrolidone carboxylates | |
| US6664280B2 (en) | Antivesicant compounds and methods of making and using thereof | |
| US2918407A (en) | Anti-spasmodics specific for upper gastrointestinal pain and spasm | |
| US4022907A (en) | Pharmaceutical compositions containing 1,3-dithiacycloalkylidene malonates | |
| US3987175A (en) | Derivatives of phenoxy isobutyric acid having hypolipemizing and hypocholesterolemizing action | |
| KR900006124B1 (ko) | Gem-디할로 및 테트라할로-1,12-디아미노-4,9-디아자-도데칸 및 이들의 제조방법 | |
| CN102234284B (zh) | 含氟的噻氯匹啶类似物及其制备方法和用途 | |
| WO2003099269A1 (en) | Cinnamic acid dimers, their preparation and the use thereof for treating neurodegenerative disease | |
| JP2023540664A (ja) | Ｉｒａｋ４阻害剤及びそれらの局所的使用方法 | |
| EP3986862A1 (en) | Succinate prodrug, compositions containing the succinate prodrug and uses thereof | |
| US20090036437A1 (en) | Pharmaceutical composition comprising phenoxazinium compound as an active ingredient | |
| EP0343303A1 (de) | Neue 1,2-Dithiol-3-thion-S-oxid-Verbindungen enthaltende Arzneimittel | |
| EP0176731A2 (de) | Pyrazoldionderivate und ihre Anwendung bei der Bekämpfung von Krankheiten | |
| NO159588B (no) | Analogifremgangsm te for fremstilling av terapeutisk aktive 5-okso-2-pyrrolidin-propansyrederivater. | |
| EP0182271B1 (de) | Neue Nb-quartäre Dibromderivate von Ajmalin, Isoajmalin, Sandwicin und Isosandwicin sowie diese Derivate enthaltende pharmazeutische Zubereitungen und Zwischenprodukte und Verfahren zu ihrer Herstellung | |
| RU2183625C2 (ru) | Изоникотиноилгидразид цитраконовой кислоты, проявляющий гипогликемическую активность | |
| KR20260057626A (ko) | 프탈라지논 화합물 및 이의 제조 방법, 약학 조성물 및 용도 |